Study of Computer-Based Treatment for Drug Dependence (RLSS)
|ClinicalTrials.gov Identifier: NCT01315184|
Recruitment Status : Completed
First Posted : March 15, 2011
Last Update Posted : February 15, 2013
|Condition or disease||Intervention/treatment||Phase|
|Opioid-Related Disorders Heroin Dependence||Behavioral: Recovery Line Support System||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||36 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Pilot Trial of a Therapeutic Interactive Voice Response System for Buprenorphine Maintenance: The Recovery Line Support System|
|Study Start Date :||July 2010|
|Actual Primary Completion Date :||July 2011|
|Actual Study Completion Date :||July 2012|
Experimental: Recovery Line Support System
Patients assigned to the Recovery Line Support System will be trained on the system and provided 24-hr access to the system for a four week period, provided with a Recovery notebook, and given reminder calls to contact the system.
Behavioral: Recovery Line Support System
Full time access (24 hours/7 days per week) to an automated, telephone-based, interactive, voice response (IVR)system for 4 weeks.
The program was developed based on a behavioral theory of substance abuse, and comprises four components: 1) self-assessment 2) learning about skills , 3) activities for current help and skills training, and 4) Feedback.
No Intervention: Treatment as Usual
Patients assigned to the TAU condition will receive any services provided by their buprenorphine provider and any additional services that their provider refers or recommends that patients attend. No additional services will be provided by the study.
- Opioid Abstinence [ Time Frame: 4 Weeks ]Continuous opioid abstinence as documented by weekly urinalysis
- Retention [ Time Frame: 4 Weeks ]Retention in the study
- Self Reported Drug Abstinent [ Time Frame: 4 weeks ]Drug Abstinence based on weekly interviews
- system use [ Time Frame: 4 weeks ]Call total amount, frequency, and specific system utilization
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01315184
|United States, Connecticut|
|New Haven, Connecticut, United States, 06519|
|Principal Investigator:||Brent A. Moore, Ph.D.||Yale University|